Evaluation of prognostic factors and the role of chemotherapy in unfavorable carcinoma of unknown primary site: A 10-year cohort study

BMC Research Notes

Volumn 5, Issue , 2012, Pages

  Chen, Kuo Wei ^a,b   Liu, Chia Jen ^a,b   Lu, Hsueh Ju ^a,b   Tzeng, Cheng Hwai ^a,b   Liu, Jin Hwang ^a,b   Chiou, Tzeon Jye ^a,b   Yen, Chueh Chuan ^a,b   Wang, Wei Shu ^b   Chao, Ta Chung ^a,b   Teng, Hao Wei ^a,b   Chen, Ming Huang ^a,b   Liu, Chun Yu ^a,b   Chang, Peter Mu Hsin ^a,b   Yang, Muh Hwa ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; LACTATE DEHYDROGENASE;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD; CANCER OF UNKNOWN PRIMARY SITE; CARCINOMA; FEMALE; HUMAN; KAPLAN MEIER METHOD; MALE; MIDDLE AGED; MORTALITY; PALLIATIVE THERAPY; PATIENT SELECTION; PROGNOSIS; PROSPECTIVE STUDY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; L-LACTATE DEHYDROGENASE; MALE; MIDDLE AGED; NEOPLASMS, UNKNOWN PRIMARY; PALLIATIVE CARE; PATIENT SELECTION; PROGNOSIS; PROSPECTIVE STUDIES;

EID: 84862803532     PISSN: None     EISSN: 17560500     Source Type: Journal    
DOI: 10.1186/1756-0500-5-70     Document Type: Review

References (27)

1. Cancer of unknown primary site. Greco FA, Hainsworth JD, DeVita, Hellman, Rosenberg's Cancer: Principles and Practice of Oncology Philadelphia: Lippincott Williams & Wilkins, DeVita Jr VT, Lawrence TS, Rosenberg SA, 6 2001 2537 2560
2. Metastases of undetermined source. Krementz ET, Cerise EJ, Foster DS, Morgan LR Jr, Curr Probl Cancer 1979 4 4 37 391494
3. Diagnostic and therapeutic management of cancer of an unknown primary. Pavlidis N, Briasoulis E, Hainsworth J, Greco FA, Eur J Cancer 2003 39 1990 2005 10.1016/S0959-8049(03)00547-1 12957453 (Pubitemid 37297755)
4. Cancer of unknown primary site. Muir C, Cancer 1995 75 1 Suppl 353 356 8001006
5. Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors. Greco FA, Pavlidis N, Semin Oncol 2009 36 65 74 10.1053/j.seminoncol.2008.10.005 19179190
6. Overview of patient management and future directions in unknown primary carcinoma. Varadhachary GR, Greco FA, Semin Oncol 2009 36 75 80 10.1053/j.seminoncol.2008.10.008 19179191
7. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. Culine S, Kramar A, Saghatchian M, et al. J Clin Oncol 2002 20 4679 4683 10.1200/JCO.2002.04.019 12488413 (Pubitemid 36025285)
8. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study. Seve P, Sawyer M, Hanson J, Broussolle C, Dumontet C, Mackey JR, Cancer 2006 106 2058 2066 10.1002/cncr.21833 16583433 (Pubitemid 43673223)
9. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site. Seve P, Ray-Coquard I, Trillet-Lenoir V, et al. Cancer 2006 107 2698 2705 10.1002/cncr.22300 17063500 (Pubitemid 44845626)
10. New prognostic index to predict survival in patients with cancer of unknown primary site with unfavourable prognosis. Trivanovi D, Petkovic M, Stimac D, Clin Oncol 2009 21 43 48 10.1016/j.clon.2008.09.007
11. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systemic chemotherapy. Kodaira M, Takahashi S, Yamada S, et al. Ann Oncol 2010 21 1163 1167 10.1093/annonc/mdp583 20019088
12. Metastatic adenocarcinomas of unknown primary site. Prognostic variables and treatment results. Kambhu SA, Kelsen DP, Fiore J, et al. Am J Clin Oncol 1990 13 55 60 10.1097/00000421-199002000-00015 2106257 (Pubitemid 20114561)
13. Unknown primary carcinoma: natural history and prognostic factors in 657 consecutive patients. Abbruzzese JL, Abbruzzese MC, Hess KR, Raber MN, Lenzi R, Frost P, J Clin Oncol 1994 12 1272 1280 8201389 (Pubitemid 24173944)
14. Simple prognostic model to predict survival in patients with undifferentiated carcinoma of unknown primary site. van der Gaast A, Verweij J, Planting AS, Hop WC, Stoter G, J Clin Oncol 1995 13 1720 1725 7541451
15. Clinical survival predictors in patients with advanced cancer. Viagano A, Bruera E, Jhangri GS, Newman SC, Fields AL, Suarez-Almazor ME, Arch Intern Med 2000 160 861 868 10.1001/archinte.160.6.861 10737287 (Pubitemid 30165248)
16. Carcinoembryonic antigen and albumin predict survival in patients with advanced colon and rectal cancer. Dixon MR, Haukoos JS, Udani SM, et al. Arch Surg 2003 138 962 966 10.1001/archsurg.138.9.962 12963652 (Pubitemid 37099870)
17. Serum albumin and CA 125 are powerful predictors of survival in epithelial ovarian cancer. Parker D, Bradley C, Bogle SM, et al. Br J Obstet Gynaecol 1994 101 888 893 10.1111/j.1471-0528.1994.tb13550.x 7999691 (Pubitemid 24316739)
18. Prognostic factors in multiple myeloma. Alexanian R, Balcerzak S, Bonnet JD, et al. Cancer 1975 36 1192 201 10.1002/1097-0142(197510)36:4<1192::AID- CNCR2820360403>3.0.CO;2-I 1175123
19. Hypercalcemia in head and neck carcinoma. Incidence and prognosis. Won C, Decker DA, Drelichman A, Al-Sarraf M, Reed ML, Cancer 1983 52 2261 2263 10.1002/1097-0142(19831215)52:12<2261::AID-CNCR2820521217>3.0.CO;2-K 6640497 (Pubitemid 14205947)
20. Hypercalcemia in patients with breast cancer: a survival study. De Wit S, Cleton FJ, J Cancer Res Clin Oncol 1994 120 610 614 10.1007/BF01212816 7929533 (Pubitemid 24281410)
21. Treatment of patients with cancer of an unknown primary site. Hainsworth JD, Greco FA, N Engl J Med 1993 329 257 263 10.1056/NEJM199307223290407 8316270 (Pubitemid 23203818)
22. Comparative survival with diverse chemotherapy regimens for cancer of unknown primary site: multiple-treatments meta-analysis. Golfinopoulos V, Pentheroudakis G, Salanti G, Nearchou AD, Ioannidis JP, Pavlidis N, Cancer Treat Rev 2009 35 570 573 10.1016/j.ctrv.2009.05.005 19539430
23. Analysis of prognostic factors in peripheral T-cell lymphoma: prognostic value of serum albumin and mediastinal lymphadenopathy. Chihara D, Oki Y, Ine S, et al. Leuk Lymphoma 2009 50 1999 2004 10.3109/10428190903318311 19860627
24. The relationship between hypoalbuminaemia, tumour volume and the systemic inflammatory response in patients with colorectal liver metastases. Al-Shaiba R, McMillan DC, Angerson WJ, Leen E, McArdle CS, Horgan P, Br J Cancer 2004 91 205 207 15213726 (Pubitemid 39037059)
25. Albumin concentrations are primarily determined by the body cell mass and the systemic inflammatory response in cancer patients with weight loss. McMillan DC, Watson WS, O'Gorman P, Preston T, Scott HR, McArdle CS, Nutr Cancer 2001 39 210 213 10.1207/S15327914nc392-8 11759282 (Pubitemid 33694037)
26. Prognostic significance of serum lactate dehydrogenase in malignant lymphoma. Schneider RJ, Seibert K, Passe S, et al. Cancer 1980 46 139 143 10.1002/1097-0142(19800701)46:1<139::AID-CNCR2820460122>3.0.CO;2-8 6992974 (Pubitemid 10080449)
27. Neuroendocrine carcinoma of unknown primary: a systematic review of the literature and a comparative study with other neuroendocrine tumors. Stoyianni A, Pentheroudakis G, Pavlidis N, Cancer Treat Rev 2011 37 358 65 10.1016/j.ctrv.2011.03.002 21481536